InVivo Therapeutics Neurosurgeon Receives MDHonors Grant For Applying Hydrogels to Spinal Cord Injury

InVivo Therapeutics Neurosurgeon Receives MDHonors Grant For Applying Hydrogels to Spinal Cord Injury

<0> InVivo TherapeuticsBob Housler, Jr., 617-863-5520 </0>

, a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma, announced today that one of the company’s neurosurgeons, Amer Khalil, MD, has been selected as the winner of an MDH Research Award, a grant given by MDHonors, to further InVivo’s research on spinal cord injury.

Dr. Khalil was awarded a grant of $10,000 for his project titled “Spinal cord repair using biomaterial-based drug-releasing strategies for reducing scarring and promoting regeneration.” Dr. Khalil’s project is important not only for InVivo’s second SCI product but also for the third product in the company’s portfolio, a platform intended for the reduction of fibrosis which has been developed to reduce scarring in both reparative surgical and dermatological applications. Combining the need for minimizing scarring after reparative surgery and the fast growing market demand for minimizing scarring following plastic surgery procedures, InVivo believes that this technology will result in millions of treatments per day in the U.S., and the company intends to lead the space.

“Amer has contributed to our team for over a year now, and we’re proud to see his peer researchers acknowledge what we see every day at InVivo,” said InVivo CEO Frank Reynolds. “Neurosurgeons have many career path options, and Amer’s commitment to helping move the ball forward in neurotrauma research makes him the perfect recipient for the MDHonors Research Award. This award clearly underscores the importance of InVivo’s spinal cord injury projects, and highlights Amer’s vital contributions to our efforts. This grant takes Amer one step further in his career as a surgeon-scientist and we’re delighted his contributions to our team are being recognized.”

InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit .

MDHonors is a division of LeadPhysician, an international physician organization based in London, which comprises more than 500,000 members. LeadPhysician is a leading online panel of practicing physicians who participate in medical research surveys for companies in the medical industry.

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.